Trial Profile
An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary)
- Indications Scleritis
- Focus Therapeutic Use
- Acronyms ATLAS
- 19 Oct 2023 Planned End Date changed from 8 Dec 2023 to 8 Dec 2024.
- 19 Oct 2023 Planned primary completion date changed from 8 Dec 2023 to 8 Dec 2024.
- 09 Jul 2022 Planned End Date changed from 1 Jun 2022 to 8 Dec 2023.